Synonym
Necrostatin-7; Necrostatin 7; Necrostatin7; Nec-7; Nec 7; Nec7;
IUPAC/Chemical Name
5-((3-(4-Fluorophenyl)-1H-pyrazol-4-yl)methylene)-2-imino-3-(thiazol-2-yl)thiazolidin-4-one
InChi Key
SMJGLNVGTJLIRV-KBEFMPHXSA-N
InChi Code
InChI=1S/C16H10FN5OS2/c17-11-3-1-9(2-4-11)13-10(8-20-21-13)7-12-14(23)22(15(18)25-12)16-19-5-6-24-16/h1-8,18H,(H,20,21)/b12-7-,18-15?
SMILES Code
O=C1N(C2=NC=CS2)C(S/C1=C\C3=CNN=C3C4=CC=C(F)C=C4)=N
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Biological target:
Necrotatin-7 (Nec-7) is a potent necroptosis inhibitor with an EC50 of 10.6 μM.
In vitro activity:
Necroptosis is a regulated caspase-independent cell death mechanism characterized by morphological features resembling non-regulated necrosis. Necrotatin-7 (Nec-7), a novel potent small-molecule inhibitor of necroptosis, is structurally distinct from previously described necrostatins (Nec-1, Nec-3, Nec-4 and Nec-5). This study describes a series of structural modifications and the structure-activity relationship (SAR) of the Nec-7 series for inhibiting necroptosis.
Reference: Bioorg Med Chem Lett. 2008 Sep 15;18(18):4932-5. https://pubmed.ncbi.nlm.nih.gov/18768316/
In vivo activity:
The cardioprotective effects of necroptosis inhibitor necrostatin-7 were studied in the rat model of permanent coronary occlusion. It was found that intraperitoneal injection of necrostatin-7 at a dose of 14.5 mg/kg 60 minutes prior to permanent left coronary artery occlusion reduced the amount of scar tissue and scar length in the left ventricle on the 21st day after surgery. In addition, pretreatment with necrostatin-7 resulted in decreased plasma level of N-terminal pro-brain natriuretic peptide, which points to the improvement in left ventricular function.
Reference: Ross Fiziol Zh Im I M Sechenova. 2015 Apr;101(4):408-14. https://pubmed.ncbi.nlm.nih.gov/26336739/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
78.0 |
210.01 |
|
| Ethanol |
56.0 |
150.78 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
371.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Fuji H, Ohmae S, Noma N, Takeiri M, Yasutomi H, Izumi K, Ito M, Toyomoto M, Iwaki S, Takemoto K, Seo S, Taura K, Hida S, Aoyama M, Ishihama Y, Hagiwara M, Takeda N, Hatano E, Iwaisako K, Uemoto S, Asagiri M. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation. Biochem Biophys Res Commun. 2018 Sep 5;503(2):544-549. doi: 10.1016/j.bbrc.2018.05.153. Epub 2018 Jul 7. PMID: 29800570.
2. Zheng W, Degterev A, Hsu E, Yuan J, Yuan C. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4932-5. doi: 10.1016/j.bmcl.2008.08.058. Epub 2008 Aug 22. PMID: 18768316.
3. Dmitriev YV, Karpov AA, Dracheva AV, Minasian SM, Chefu SG, Vasina LV, Demchenko EA, Galagudza IM. [CARDIOPROTFETIVE EFECTS OF NECROSTATIN-7 IN THE RAT MODEL OF PERMANENT CORONARY OCCLUSION]. Ross Fiziol Zh Im I M Sechenova. 2015 Apr;101(4):408-14. Russian. PMID: 26336739.
In vitro protocol:
1. Fuji H, Ohmae S, Noma N, Takeiri M, Yasutomi H, Izumi K, Ito M, Toyomoto M, Iwaki S, Takemoto K, Seo S, Taura K, Hida S, Aoyama M, Ishihama Y, Hagiwara M, Takeda N, Hatano E, Iwaisako K, Uemoto S, Asagiri M. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation. Biochem Biophys Res Commun. 2018 Sep 5;503(2):544-549. doi: 10.1016/j.bbrc.2018.05.153. Epub 2018 Jul 7. PMID: 29800570.
2. Zheng W, Degterev A, Hsu E, Yuan J, Yuan C. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4932-5. doi: 10.1016/j.bmcl.2008.08.058. Epub 2008 Aug 22. PMID: 18768316.
In vivo protocol:
1. Dmitriev YV, Karpov AA, Dracheva AV, Minasian SM, Chefu SG, Vasina LV, Demchenko EA, Galagudza IM. [CARDIOPROTFETIVE EFECTS OF NECROSTATIN-7 IN THE RAT MODEL OF PERMANENT CORONARY OCCLUSION]. Ross Fiziol Zh Im I M Sechenova. 2015 Apr;101(4):408-14. Russian. PMID: 26336739.
1: Fuji H, Ohmae S, Noma N, Takeiri M, Yasutomi H, Izumi K, Ito M, Toyomoto M, Iwaki S, Takemoto K, Seo S, Taura K, Hida S, Aoyama M, Ishihama Y, Hagiwara M, Takeda N, Hatano E, Iwaisako K, Uemoto S, Asagiri M. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation. Biochem Biophys Res Commun. 2018 May 22. pii: S0006-291X(18)31224-5. doi: 10.1016/j.bbrc.2018.05.153. [Epub ahead of print] PubMed PMID: 29800570.
2: Ding B, Parmigiani A, Divakaruni AS, Archer K, Murphy AN, Budanov AV. Sestrin2 is induced by glucose starvation via the unfolded protein response and protects cells from non-canonical necroptotic cell death. Sci Rep. 2016 Mar 2;6:22538. doi: 10.1038/srep22538. PubMed PMID: 26932729; PubMed Central PMCID: PMC4773760.
3: Dmitriev YV, Karpov AA, Dracheva AV, Minasian SM, Chefu SG, Vasina LV, Demchenko EA, Galagudza IM. [CARDIOPROTFETIVE EFECTS OF NECROSTATIN-7 IN THE RAT MODEL OF PERMANENT CORONARY OCCLUSION]. Ross Fiziol Zh Im I M Sechenova. 2015 Apr;101(4):408-14. Russian. PubMed PMID: 26336739.
4: Zheng W, Degterev A, Hsu E, Yuan J, Yuan C. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4932-5. doi: 10.1016/j.bmcl.2008.08.058. Epub 2008 Aug 22. PubMed PMID: 18768316.
